PL3484862T3 - Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią - Google Patents

Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią

Info

Publication number
PL3484862T3
PL3484862T3 PL17831578T PL17831578T PL3484862T3 PL 3484862 T3 PL3484862 T3 PL 3484862T3 PL 17831578 T PL17831578 T PL 17831578T PL 17831578 T PL17831578 T PL 17831578T PL 3484862 T3 PL3484862 T3 PL 3484862T3
Authority
PL
Poland
Prior art keywords
hyperuricemia
gout
compositions
treating
compounds
Prior art date
Application number
PL17831578T
Other languages
English (en)
Inventor
Shunqi Yan
Li-Tain Yeh
Robert Orr
Original Assignee
Arthrosi Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrosi Therapeutics, Inc. filed Critical Arthrosi Therapeutics, Inc.
Publication of PL3484862T3 publication Critical patent/PL3484862T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PL17831578T 2016-07-18 2017-07-12 Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią PL3484862T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363473P 2016-07-18 2016-07-18
EP17831578.4A EP3484862B1 (en) 2016-07-18 2017-07-12 Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
PCT/US2017/041763 WO2018017368A1 (en) 2016-07-18 2017-07-12 Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia

Publications (1)

Publication Number Publication Date
PL3484862T3 true PL3484862T3 (pl) 2022-01-31

Family

ID=60992707

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17831578T PL3484862T3 (pl) 2016-07-18 2017-07-12 Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią

Country Status (15)

Country Link
US (7) US10239854B2 (pl)
EP (2) EP3957629B1 (pl)
JP (3) JP2019524747A (pl)
KR (1) KR102610573B1 (pl)
CN (3) CN109790135B (pl)
AU (1) AU2017298142B2 (pl)
CA (1) CA3030821A1 (pl)
DK (1) DK3484862T3 (pl)
EA (1) EA201990333A1 (pl)
ES (2) ES2897968T3 (pl)
IL (1) IL264268B (pl)
PL (1) PL3484862T3 (pl)
PT (1) PT3484862T (pl)
SG (1) SG11201900405XA (pl)
WO (1) WO2018017368A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2988050A1 (en) 2015-06-09 2016-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
AU2017298142B2 (en) 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
KR20210100677A (ko) * 2018-12-06 2021-08-17 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
CN113164439A (zh) * 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
JP2022533958A (ja) * 2019-05-14 2022-07-27 アースローシ セラピューティクス，インク． 痛風または高尿酸血症を処置するための化合物
CA3138419A1 (en) * 2019-06-17 2020-12-24 Fochon Pharmaceuticals, Ltd. Heterocyclic derivatives and use thereof
TW202214228A (zh) * 2020-06-10 2022-04-16 美商安索治療公司 治療或預防慢性腎臟病之方法
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
TW202330485A (zh) * 2021-12-02 2023-08-01 美商安索治療公司 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia
WO2023149549A1 (ja) * 2022-02-03 2023-08-10 国立大学法人富山大学 新規医薬組成物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023985A (en) 1911-05-29 1912-04-23 Louis Emile Beaulieu Fish-plate bolt.
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
KR0182801B1 (ko) 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
JPH07501073A (ja) 1991-11-22 1995-02-02 プロクター、エンド、ギャンブル、ファーマス−ティカルズ、インコーポレーテッド リゼドロネート遅延放出組成物
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE69332291T2 (de) 1992-10-16 2003-07-31 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung von wachsmatrizes
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
EP0827402A2 (en) 1995-05-17 1998-03-11 Cedars-Sinai Medical Center Compositions containing fatty acids for improving digestion and absorption in the small intestine
DE19624292A1 (de) * 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1767531A4 (en) * 2004-06-10 2011-01-05 Torii Pharmaceutical Co Ltd MEDICINAL COMPOSITIONS CONTAINING 6-HYDROXYBENZBROMARONE OR SALTS THEREOF
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
AU2008245662A1 (en) * 2007-04-26 2008-11-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
JP5325065B2 (ja) * 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
GB2484298A (en) 2010-10-05 2012-04-11 Plexus Ocean Syst Ltd Subsea wellhead with adjustable hanger forming an annular seal
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US20150031768A1 (en) 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
US9725430B2 (en) 2013-01-16 2017-08-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
US20140357683A1 (en) * 2013-05-31 2014-12-04 Takeda Pharmaceuticals U.S.A., Inc. Methods of treatment and compositions with xanthine oxidase inhibitors
WO2015134467A1 (en) * 2014-03-05 2015-09-11 The Trustees Of Princeton University Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
RU2017105133A (ru) 2014-07-31 2018-08-28 Мерк Патент Гмбх Индолизиновые производные, которые применяют при нейродегенеративных заболеваниях
CN104311516B (zh) 2014-09-16 2017-01-11 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
CN104262305B (zh) 2014-09-16 2016-06-08 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
AU2017298142B2 (en) 2016-07-18 2021-11-11 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
CN113164439A (zh) 2018-12-06 2021-07-23 安索治疗公司 用于治疗或预防痛风或高尿酸血症的方法
KR20210100677A (ko) 2018-12-06 2021-08-17 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형

Also Published As

Publication number Publication date
EP3484862A4 (en) 2020-01-22
EA201990333A1 (ru) 2019-10-31
CA3030821A1 (en) 2018-01-25
AU2017298142A1 (en) 2019-02-28
JP7418227B2 (ja) 2024-01-19
ES2897968T3 (es) 2022-03-03
US20190169150A1 (en) 2019-06-06
US20200148659A1 (en) 2020-05-14
AU2017298142B2 (en) 2021-11-11
US20220396558A1 (en) 2022-12-15
US20240116888A1 (en) 2024-04-11
CN113214198A (zh) 2021-08-06
EP3957629A1 (en) 2022-02-23
US11236058B2 (en) 2022-02-01
US10239854B2 (en) 2019-03-26
KR102610573B1 (ko) 2023-12-05
JP2022188052A (ja) 2022-12-20
EP3957629B1 (en) 2023-09-06
US20230227419A1 (en) 2023-07-20
WO2018017368A1 (en) 2018-01-25
ES2964344T3 (es) 2024-04-05
CN113214198B (zh) 2022-12-23
PT3484862T (pt) 2021-11-17
US10508093B2 (en) 2019-12-17
US20220112171A1 (en) 2022-04-14
JP2020143044A (ja) 2020-09-10
CN109790135A (zh) 2019-05-21
EP3484862B1 (en) 2021-09-01
KR20190020170A (ko) 2019-02-27
IL264268B (en) 2022-08-01
EP3484862A1 (en) 2019-05-22
CN109790135B (zh) 2023-07-28
JP2019524747A (ja) 2019-09-05
SG11201900405XA (en) 2019-02-27
US20190040030A1 (en) 2019-02-07
IL264268A (en) 2019-02-28
EP3957629C0 (en) 2023-09-06
CN116332886A (zh) 2023-06-27
DK3484862T3 (da) 2021-11-08
WO2018017368A9 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
PL3484862T3 (pl) Związki, kompozycje i sposoby leczenia lub zapobiegania objawowi związanemu z dną moczanową lub hiperurykemią
PT3348557T (pt) Imidazo[1,2a]piridinas para o tratamento ou prevenção de hiperuricemia ou gota
EP3501527C0 (en) COMPOSITION FOR PREVENTING OR TREATING A MENTAL DISORDER, CONTAINING A VESICLE DERIVED FROM BACTERIA OF AN ELACTOBACILLUS SPECIES
PL3283551T3 (pl) Kompozycja aktywowanej ligniny, sposób jej wytwarzania oraz jej zastosowanie
IL287983A (en) 15-hepe or a preparation containing 15-hepe for the treatment or prevention of fibrosis
HK1252692A1 (zh) 治療或者預防蛋白質構象病的方法
IL283665A (en) Methods for treating or preventing rheumatism or hyperuricemia
ZA201907975B (en) Agent for preventing or treating tauopathy
KR101675359B9 (ko) 네오아가로올리고당을 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물
GB201410099D0 (en) Dock gate
IL251648A0 (en) A preparation for treating an anti-material template and a method for creating a template using it
EP3148525C0 (en) CAFESTOL FOR TREATING DIABETES
PL3129467T3 (pl) Wysepki od świni transgenicznej i ich zastosowania w leczeniu cukrzycy
IL262664B (en) Compounds for the treatment of preventing symptoms of changes in blood vessel diameter
EP3369419C0 (en) COMPOSITION FOR THE TREATMENT OF DIABETES
PT3414155T (pt) Mordente de corrente melhorado
EP3255055C0 (en) COMPOSITION INTENDED TO IMPROVE MEMORY, LEARNING ABILITY AND COGNITION
IL275258A (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF VASOMOTOR SYMPTOMS
EP3823648C0 (en) METHODS FOR THE TREATMENT OF DIABETES
ZA201802090B (en) A composition and method for treating substrates
ZA201706716B (en) A composition and method for treating substrates
PL3449155T3 (pl) Łącznik łańcucha
GB201405438D0 (en) Herbicidal composition, a method for its preperation and the use thereof
PL3172353T3 (pl) Sposób obróbki elementu azotowanego/azotonawęglanego
SG10201403858RA (en) Compound, composition and method for treating and/or ameliorating kidney disease